Navigation Links
Syndax Promotes John S. Pallies to Chief Financial Officer and Dr. Peter Ordentlich to Chief Technology Officer
Date:11/1/2013

WALTHAM, Mass., Nov. 1, 2013 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. today announced the promotion of John S. Pallies to chief financial officer from vice president, finance and administration, and co-founder Peter Ordentlich, Ph.D., to chief technology officer from vice president, translational medicine. Both appointments are effective Nov.1, 2013.

"These promotions are recognition of the exceptional work John and Peter have done helping Syndax develop to the point of being ready to begin a Phase 3 trial of entinostat in patients with advanced breast cancer," said Arlene M. Morris, Syndax's chief executive officer. "John has been leading the financial operations of Syndax for more than six years and Peter co-founded the company based on scientific discoveries at the Salk Institute for Biological Studies. We are confident John's financial insight and strategic aptitude and Peter's unique clinical and scientific expertise will help Syndax continue successful development of entinostat for the treatment of breast cancer and other malignancies."

Mr. Pallies joined Syndax in 2007 with more than a decade of experience in biotech, high-tech start-ups and management consulting focused on developing corporate and financial infrastructures and managing multiple business operations. Prior to co-founding Syndax in 2005, Dr. Ordentlich was a scientist at the Salk Institute for Biological Studies in La Jolla, California, working with Dr. Ronald M. Evans to identify small molecules as potential therapeutics and evaluating synergistic combinations of histone deacetylase inhibitors and nuclear receptor ligands.

About Syndax Pharmaceuticals

Syndax is late stage biopharmaceutical company focused on the development and commercialization of its lead product candidate, entinostat, an epigenetic therapy for treatment-resistant cancers. Entinostat was recently granted Breakthrough Therapy designation by the U.S. Food and Drug Administration.

Corporate Contact:
Bob Goodenow
Chief Business Officer
Syndax Pharmaceuticals
(781) 419-1418
BGoodenow@Syndax.com

Media Contacts:
David Schull or Matt Middleman, M.D.
Russo Partners
(212) 845-4271
(212) 845-4272
david.schull@russopartnersllc.com  
matt.middleman@russopartnersllc.com


'/>"/>
SOURCE Syndax Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Syndaxs Entinostat Receives Breakthrough Therapy Designation from FDA for Treatment of Advanced Breast Cancer
2. Syndax and Eddingpharm Enter into a License Agreement Giving Eddingpharm Rights to Commercialize Entinostat in China and Other Asian Countries
3. Syndax Pharmaceuticals Secures $26.6 Million Series B Financing for Advancement of Epigenetic Therapies for Treatment-Resistant Cancers
4. Syndax Pharmaceuticals Announces Publication of Clinical Study Demonstrating that Entinostat Targets Resistance Pathways in Breast Cancer
5. Syndax Pharmaceuticals to Present Updated Overall Survival Data With Entinostat in Metastatic Breast Cancer at ASCO
6. Medela Promotes Human Milk Consumption in NICUs to Address Health Risks Associated with Prematurity and Improve Infant Health
7. SynteractHCR Promotes Education to Take Time and Cost out of Drug Development with ICD+ Webinar Series
8. Kepner-Tregoe, Inc. Promotes Chris Geraghty to Chief Executive Officer
9. Lower Extremity Functional Electrical Stimulation Cycling Promotes Physical & Neurological Recovery in Chronic Spinal Cord Injury
10. OncoSec Medical Promotes Veronica Vallejo to Chief Financial Officer
11. Biomarkers in Drug Discovery - Integration in Early Stage Promotes Use of Companion Diagnostics to Optimize Therapeutic Outcomes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... North America , ... The global market is expected to reach USD 20,190.1 Million by ... of 10.2%. --> North America , ... MarketsandMarkets, The global market is expected to reach USD 20,190.1 Million ... CAGR of 10.2%. --> According to a new market ...
(Date:2/11/2016)... , February 11, 2016 ... Market Report 2016 research report provides information on ... development status with crucial statistical data and information ... http://www.deepresearchreports.com/142870.html . --> Complete report on ... companies and supported with 296 tables and figures ...
(Date:2/10/2016)... , Feb. 11, 2016  QT Vascular Ltd., together ... and together with its subsidiaries, the "Group"), is ... litigation with AngioScore, Inc. ("ÄngioScore") (now owned by ... the United States Court ... Circuit") reversed an earlier district court order (the ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... ... As part of their 2015 end of year funding strategy, Colleen’s ... gifted $10,000 to University of Chicago to support ovarian cancer research being conducted by ... honored to support a promising young investigator from Dr. Lengyel’s lab at the University ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... the World Molecular Imaging Congress (WMIC), will be held in New York City, ... is “Imaging Biology…Improving Therapy.” The congress will highlight and emphasize how imaging reveals ...
(Date:2/10/2016)... ... 2016 , ... Early this week, Team Iconic at J. Walter Thompson and ... the first global confectionery brand sourced from 100% sustainable cocoa. , The Nestlé Cocoa ... product, through activities that focus on better farming, better lives and better cocoa. In ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... offering education, research and medical media, has launched Contagion® , a ... diseases. , As the all-inclusive resource for infectious disease information, Contagion features ...
(Date:2/10/2016)... ... February 10, 2016 , ... MetLoop CEO ... new 2.0 version at the International Roofing Expo in Orlando, Florida on February ... world's most advanced weather technology in the hands of consumers, roofing contractors, manufacturers ...
Breaking Medicine News(10 mins):